Which chronic kidney disease (CKD) patients is Farxiga approved for?
Farxiga (dapagliflozin) is an SGLT2 inhibitor used in CKD to help slow progression of kidney disease and reduce certain kidney-related outcomes. It is intended for patients with chronic kidney disease who are at risk of progression, including people with reduced kidney function.
What does the CKD indication cover (kidney vs. heart outcomes)?
The CKD indication is specifically aimed at kidney outcomes (slowing kidney decline and reducing kidney events). Farxiga can also have separate approved indications for heart failure and type 2 diabetes, but those are different from the CKD indication.
Is Farxiga’s CKD use limited by eGFR or albumin levels?
CKD approvals for SGLT2 inhibitors are typically tied to kidney function thresholds and the trial populations studied (for example, lower eGFR ranges and/or albuminuria). The exact label wording matters for which CKD stages and patient characteristics are covered.
What alternatives might be considered for CKD if Farxiga isn’t appropriate?
If Farxiga isn’t suitable (for example, due to kidney function constraints on-label, intolerance, or other contraindications), clinicians commonly consider other CKD-focused therapies, including blood pressure control and renin-angiotensin system blockade when appropriate, plus other diabetes and kidney medications depending on the patient’s overall condition.
Patent and exclusivity research (if you’re looking for branded/market timing)
If you’re researching Farxiga’s market exclusivity or patent status, DrugPatentWatch.com tracks patent listings and status for branded drugs like Farxiga: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Farxiga (dapagliflozin) patent research